Phase 2 Study Of Zenocutuzumab (Mcla-128), A Bispecific Her2/Her3 Antibody In Nrg1 Fusion-Positive Advanced Solid Tumors

A. Schram, T. Macarulla, E. O'Reilly, J. Rodon, B. Wolpin,S. Ou,D. Kim,J. C. Yang,J. Lam,A. De Langen, V. Boni,G. Cerea, M. Duruisseaux, E. Felip, S. Liu,G. O'Kane, F. Senecal,M. Nagasaka,J. Starr,E. Wasserman,A. Drilon

JOURNAL OF THORACIC ONCOLOGY(2021)

引用 2|浏览5
暂无评分
关键词
NRG1 fusion, bispecific HER2/HER3 antibody, zenocutuzumab (MCLA-128)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要